Gynecologic Cancers

A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.

Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.

In this interview we discuss the idea behind an enhanced recovery program for patients undergoing cytoreductive surgery for ovarian cancer, as well as some of the potential cost savings.

We spoke with Dr. Elizabeth Swisher about the ARIEL2 trial and the role of rucaparib in ovarian cancer.

Women who receive two doses of HPV vaccine have higher prophylactic efficacy than women who receive only one dose, according to a database study.

The use of sentinel lymph node biopsy alone in women with early cervical cancer resulted in less surgical morbidity without a significant increase in the risk of recurrence, according to a new prospective study.

Treating women with stage IVB cervical cancer with whole pelvic radiation along with standard chemotherapy improved survival over chemotherapy alone in a retrospective study.

Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.

Researchers have identified a protein that may respond to PI3K/mTOR inhibitors for patients with a specific type of uterine sarcoma.

California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.

A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA in patients with recurrent high-grade serous ovarian cancer. Those reversion mutations can help predict poor response to therapy in these patients.

Woman who undergo bilateral removal of ovaries at the time of hysterectomy have higher risks of all-cause mortality afterward, including hospital admission for ischemic heart disease.

Intentional weight loss can lower the risk of endometrial cancer in postmenopausal women, according to a new study. This was especially true of obese women who lost weight.

An analysis of Lynch syndrome–associated ovarian cancer found that the malignancy tends to present at an early stage and has a generally good prognosis.

Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.

In this interview we discuss a recent study that found that more than half of patients with locally advanced cervical cancer in the United States did not receive standard of care.

The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.

A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.